Cancer Treatment Antibody Articles & Analysis
6 news found
Initial anti-glycan mAbs from the GlyMab™ platform have now been successfully humanised Fourth research agreement on Glymab™ platform signed with major European Pharma Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its anti-glycan monoclonal ...
ByScancell
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) ...
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies MacroGenics to combine proprietary antibody and bispecific DART® technology with Synaffix’s linker-payload technologies to develop up to three next generation conjugates Total potential deal value of up to $586 million, plus royalties on commercial sales Synaffix ...
January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of ...
(Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that LAVA and The Antibody Society, a non-profit association, are co-organizing a virtual symposium Emerging cancer therapies leveraging gamma-delta effector T cells taking place on Mon., Nov. 29, 2021 from 11 a.m. to 2 p.m. ...
(known as MSD outside the United States and Canada, through an affiliate) to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this collaboration will be evaluated as part of the clinical development program for Merck & Co.'s ...